Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03056742
Other study ID # SRPL/CLI/10-11/001 Version 4
Secondary ID
Status Withdrawn
Phase Phase 2
First received January 23, 2017
Last updated April 5, 2017
Start date February 20, 2017
Est. completion date October 2019

Study information

Verified date April 2017
Source Stempeutics Research Pvt Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being conducted as an extension of the phase II clinical trial SRPL/CLI/10-11/001 (NCT01484574). The CDSCO has recommended flexibility for continued clinical study in consultation with ICMR, as per recommendation of Cellular biology based therapeutic drug evaluation committee (CBBTDEC).


Description:

This study will evaluate the safety and efficacy of intramuscular injection of stempeucel(R) (Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells) in Critical Limb Ischemia due to Buerger's Disease


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Stempeucel(R)
Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells

Locations

Country Name City State
India Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals Bangalore Karnataka
India Department of Vascular Surgery, Madras Medical College Chennai Tamil Nadu
India Department of Vascular Surgery, Sri Ramchandra Medical College Chennai Tamil Nadu
India Saveetha Medical College & Hospital Chennai Tamil Nadu
India SRM Medical College Hospital and Research Centre Chennai Tamil Nadu
India Health Point Hospital Kolkata West Bengal
India Nightingale Hospital Kolkata West Bengal
India Department of Surgical Disciplines, All India Institute of Medical Sciences New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Stempeutics Research Pvt Ltd

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s). 6 months and 24 months
Other CVS mortality 6 months and 24 months
Other All-cause mortality 6 months and 24 months
Primary Relief of the rest pain 6 months
Primary Reduction of ulcer area in the target limb 6 months
Secondary Total walking distance 6 months and 24 months
Secondary Major amputation free survival 6 months and 24 months
Secondary Ankle brachial pressure index (ABPI) - measured by Doppler 6 months and 24 months
Secondary Quality of life (QOL) by King's College VascuQOL questionnaire 6 months and 24 months
Secondary Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA) 6 months and 24 months